In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 5.29 above Abivax Sa average.

Within Major Pharmaceutical Preparations industry 114 other companies have achieved higher Quick Ratio than Abivax Sa in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 430, from total ranking in the third quarter 2025 at 1439.

Explain Quick Ratio?
How much Cash & cash equivalents ABVX�s has?
What are ABVX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ABVX/financial-strength

https://api.csimarket.com/api/v1/companies/ABVX/fundamentals

https://api.csimarket.com/api/v1/companies/ABVX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ABVX Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	-23.89 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	306.2 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	5.29	Subscribe	Subscribe	Subscribe	Subscribe
ABVX's Total Ranking	# 430	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	62.44 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-12.37 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 115
Healthcare Sector	# 179
Overall Market	# 430

Quick Ratio Statistics
High	Average	Low
8.2	4.44	1.53
(Dec 31 2025)		(Dec 31 2024)

Financial Statements
Abivax Sa's Current Liabilities	$ 115 Millions	Visit ABVX's Balance sheet
Abivax Sa's Cash & cash equivalent	$ 606 Millions	Visit ABVX's Balance sheet
Source of ABVX's Sales		Visit ABVX's Sales by Geography

Cumulative Abivax Sa's Quick Ratio

ABVX's Quick Ratio for the trailling 12 Months

ABVX Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-30.03 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	287.43 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	7.52	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 195	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-9.93 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	22.87 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ABVX Financial Strength Comparisons >> Go to Compare ABVX Quick Ratio to its Competitors

On the trailing twelve months basis ABVX Cash & cash equivalent more than doubled by 306.2 % in Q4 2025 year on year, while Current Liabilities soared to $115 millions, this led to increase in in Abivax Sa's Quick Ratio to 7.52, above ABVX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 464 other companies have achieved higher Quick Ratio than Abivax Sa. While Quick Ratio overall ranking has improved so far to 2820, from total ranking during the twelve months ending third quarter 2025 at 3491.

Explain Quick Ratio?
How much Cash & cash equivalents ABVX�s has?
What are ABVX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 465
Healthcare Sector	# 939
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
8.2	4.87	1.53
(Dec 31 2025)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Cryoport inc	14.54	$ 413.300 Millions	$ 28.426 Millions
Eupraxia Pharmaceuticals Inc	14.51	$ 80.563 Millions	$ 5.551 Millions
Climb Bio Inc	14.47	$ 101.080 Millions	$ 6.984 Millions
Synlogic Inc	14.41	$ 14.668 Millions	$ 1.018 Millions
Cervomed Inc	14.35	$ 20.864 Millions	$ 1.454 Millions
Bicara Therapeutics Inc	14.33	$ 414.801 Millions	$ 28.949 Millions
Tyra Biosciences Inc	14.15	$ 256.003 Millions	$ 18.094 Millions
Cogent Biosciences Inc	14.08	$ 900.765 Millions	$ 63.953 Millions
Keros Therapeutics Inc	14.08	$ 287.415 Millions	$ 20.414 Millions
Amylyx Pharmaceuticals Inc	13.97	$ 316.979 Millions	$ 22.688 Millions
Oric Pharmaceuticals Inc	13.79	$ 281.488 Millions	$ 20.417 Millions
Vtv Therapeutics Inc	13.39	$ 88.932 Millions	$ 6.641 Millions
Agios Pharmaceuticals Inc	13.39	$ 854.425 Millions	$ 63.814 Millions
Vera Therapeutics Inc	13.37	$ 714.589 Millions	$ 53.455 Millions
Chemocentryx Inc.	13.22	$ 0.736 Millions	$ 0.056 Millions
Dianthus Therapeutics Inc	13.16	$ 404.295 Millions	$ 30.732 Millions
Rallybio Corporation	12.96	$ 54.736 Millions	$ 4.223 Millions
Mirum Pharmaceuticals Inc	12.87	$ 732.452 Millions	$ 56.890 Millions
Damora Therapeutics Inc	12.84	$ 257.624 Millions	$ 20.066 Millions
Aptevo Therapeutics Inc	12.77	$ 42.119 Millions	$ 3.298 Millions
Immuneering Corporation	12.77	$ 128.645 Millions	$ 10.074 Millions
Harmony Biosciences Holdings inc	12.69	$ 775.340 Millions	$ 61.093 Millions
Chemomab Therapeutics Ltd	12.61	$ 10.366 Millions	$ 0.822 Millions
Protagonist Therapeutics inc	12.49	$ 567.364 Millions	$ 45.441 Millions
Pulmatrix Inc	12.43	$ 4.088 Millions	$ 0.329 Millions
Bridgebio Oncology Therapeutics Inc	12.14	$ 425.460 Millions	$ 35.041 Millions
Vyne Therapeutics Inc	12.11	$ 29.008 Millions	$ 2.395 Millions
Crinetics Pharmaceuticals Inc	12.08	$ 1,027.889 Millions	$ 85.072 Millions
Arrivent Biopharma inc	12.06	$ 312.821 Millions	$ 25.931 Millions
Kailera Therapeutics Inc	12.04	$ 546.056 Millions	$ 45.365 Millions

Date modified: 2026-10-15T05:23:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.